Natural history and treatment of cutaneous and systemic mastocytosis

References

• Tamay Z, Ozceker D. Current approach to cutaneous mastocytosis in childhood. Turk Pediatri Ars. 2016;51(3):123–127.
   PubMedGoogle Scholar
• Brockow K. Epidemiology, prognosis, and risk factors in mastocytosis. Immunol Allergy Clin North Am. 2014;34(2):283–295.
   PubMed Web of Science ®Google Scholar
• Georgin-Lavialle S, Lhermitte L, Dubreuil P, et al. Mast cell leukemia. Blood. 2013;121(8):1285–1295.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Tefferi A. Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature. Curr Opin Hematol. 2010;17(2):125–132.
   PubMed Web of Science ®Google Scholar
• Nettleship ETW. Rare forms of urticaria. Br Med J. 1869;ii:323–330.
   Google Scholar
• Middelkamp Hup MA, Heide R, Tank B, et al. Comparison of mastocytosis with onset in children and adults. J Eur Acad Dermatol Venereol. 2002;16(2):115–120.
   PubMed Web of Science ®Google Scholar
• Akoglu G, Erkin G, Cakir B, et al. Cutaneous mastocytosis: demographic aspects and clinical features of 55 patients. J Eur Acad Dermatol Venereol. 2006;20(8):969–973.
   PubMed Web of Science ®Google Scholar
• Lange M, Nedoszytko B, Gorska A, et al. Mastocytosis in children and adults: clinical disease heterogeneity. Arch Med Sci. 2012;8(3):533–541.
   PubMed Web of Science ®Google Scholar
• Azana JM, Torrelo A, Mediero IG, et al. Urticaria pigmentosa: a review of 67 pediatric cases. Pediatr Dermatol. 1994;11(2):102–106.
   PubMed Web of Science ®Google Scholar
• Ben-Amitai D, Metzker A, Cohen HA. Pediatric cutaneous mastocytosis: a review of 180 patients. Isr Med Assoc J. 2005;7(5):320–322.
   PubMed Web of Science ®Google Scholar
• Kiszewski AE, Duran-Mckinster C, Orozco-Covarrubias L, et al. Cutaneous mastocytosis in children: a clinical analysis of 71 cases. J Eur Acad Dermatol Venereol. 2004;18(3):285–290.
   PubMed Web of Science ®Google Scholar
• Wiechers T, Rabenhorst A, Schick T, et al. Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis. J Allergy Clin Immunol. 2015;136(6):1581-90e1-3.
   PubMed Web of Science ®Google Scholar
• Lange M, Niedoszytko M, Renke J, et al. Clinical aspects of paediatric mastocytosis: a review of 101 cases. J Eur Acad Dermatol Venereol. 2013;27(1):97–102.
   PubMed Web of Science ®Google Scholar
• Lange M, Niedoszytko M, Nedoszytko B, et al. Diffuse cutaneous mastocytosis: analysis of 10 cases and a brief review of the literature. J Eur Acad Dermatol Venereol. 2012;26(12):1565–1571.
   PubMed Web of Science ®Google Scholar
• Heide R, Zuidema E, Beishuizen A, et al. Clinical aspects of diffuse cutaneous mastocytosis in children: two variants. Dermatology. 2009;219(4):309–315.
   PubMed Web of Science ®Google Scholar
• Patrizi A, Virdi A, Neri I. Cutaneous mastocytosis exacerbated by pinworms in a young boy. Pediatr Dermatol. 2012;29(2):229–230.
   PubMed Web of Science ®Google Scholar
• Patrizi A, Tabanelli M, Neri I, et al. Topical corticosteroids versus “wait and see” in the management of solitary mastocytoma in pediatric patients: a long-term follow-up. Dermatol Ther. 2015;28(2):57–61.
   PubMed Web of Science ®Google Scholar
• Oku T, Hashizume H, Yokote R, et al. The familial occurrence of bullous mastocytosis (diffuse cutaneous mastocytosis). Arch Dermatol. 1990;126(11):1478–1484.
   PubMedGoogle Scholar
• Cohen SS, Skovbo S, Vestergaard H, et al. Epidemiology of systemic mastocytosis in Denmark. Br J Haematol. 2014;166(4):521–528.
   PubMed Web of Science ®Google Scholar
• Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129(11):1420–1427.
   PubMed Web of Science ®Google Scholar
• Magliacane D, Parente R, Triggiani M. Current concepts on diagnosis and treatment of mastocytosis. Translational Medicine @ UniSa. 2014;8:65–74.
   PubMedGoogle Scholar
• Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37(6):435–453.
   PubMed Web of Science ®Google Scholar
• Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157(3):215–225.
   PubMed Web of Science ®Google Scholar
• Alotaibi L, Alali F, AbdullGaffar B, et al. Combined central xanthomatous and peripheral macular skin lesions in an infant. Int J Dermatol. 2014;53(6):673–675.
   PubMed Web of Science ®Google Scholar
• Guler E, Emir S, Kutluk T, et al. Urticaria pigmentosa associated with Wilms tumor. Pediatr Dermatol. 2001;18(4):313–315.
   PubMed Web of Science ®Google Scholar
• Frigui M, Dupin N, Carlotti A, et al. Telangiectasic mastocytosis with systemic sclerosis. Presse Med. 2013;42(5):902–904.
   PubMed Web of Science ®Google Scholar
• Mann C, Sepp N, Simma B. Congenital cutaneous mastocytosis. J Pediatr. 2004;145(1):134.
   PubMed Web of Science ®Google Scholar
• Verma KK, Bhat R, Singh MK. Bullous mastocytosis treated with oral betamethasone therapy. Indian J Pediatr. 2004;71(3):261–263.
   PubMedGoogle Scholar
• Has C, Misery L, David L, et al. Recurring staphylococcal scalded skin syndrome-like bullous mastocytosis: the utility of cytodiagnosis and the rapid regression with steroids. Pediatr Dermatol. 2002;19(3):220–223.
   PubMed Web of Science ®Google Scholar
• Tuxen AJ, Orchard D. Solitary mastocytoma occurring at a site of trauma. Australas J Dermatol. 2009;50(2):133–135.
   PubMed Web of Science ®Google Scholar
• Prignano F, Troiano M, Lotti T. Cutaneous mastocytosis: successful treatment with narrowband ultraviolet B phototherapy. Clin Exp Dermatol. 2010;35(8):914–915.
   PubMed Web of Science ®Google Scholar
• Gobello T, Mazzanti C, Sordi D, et al. Medium- versus high-dose ultraviolet A1 therapy for urticaria pigmentosa: a pilot study. J Am Acad Dermatol. 2003;49(4):679–684.
   PubMed Web of Science ®Google Scholar
• Tuchinda C, Kerr HA, Taylor CR, et al. UVA1 phototherapy for cutaneous diseases: an experience of 92 cases in the United States. Photodermatol Photoimmunol Photomed. 2006;22(5):247–253.
   PubMed Web of Science ®Google Scholar
• Kinsler VA, Hawk JL, Atherton DJ. Diffuse cutaneous mastocytosis treated with psoralen photochemotherapy: case report and review of the literature. Br J Dermatol. 2005;152(1):179–180.
   PubMed Web of Science ®Google Scholar
• Valent P, Cerny-Reiterer S, Hoermann G, et al. Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT. Am J Blood Res. 2014;4(2):93–100.
   PubMedGoogle Scholar
• Florian S, Esterbauer H, Binder T, et al. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib. Leuk Res. 2006;30(9):1201–1205.
   PubMed Web of Science ®Google Scholar
• Inaoui R, Petit B, Jaccard A, et al. Aggressive systemic mastocytosis. Joint Bone Spine. 2003;70(1):64–66.
   PubMed Web of Science ®Google Scholar
• Mickys U, Barakauskiene A, De Wolf-Peeters C, et al. Aggressive systemic mastocytosis complicated by protein-losing enteropathy. Dig Liver Dis. 2007;39(7):693–697.
   PubMedGoogle Scholar
• Rudzki Z, Sotlar K, Kudela A, et al. Systemic mastocytosis (SM) and associated malignant bone marrow histiocytosis - a hitherto undescribed form of SM-AHNMD. Pol J Pathol. 2011;62(2):101–104.
   PubMed Web of Science ®Google Scholar
• Yoshida C, Takeuchi M, Tsuchiyama J, et al. Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha. Intern Med. 2009;48(22):1973–1978.
   PubMed Web of Science ®Google Scholar
• Lieberoth S, Thomsen SF. Cutaneous and gastrointestinal symptoms in two patients with systemic mastocytosis successfully treated with omalizumab. Case Rep Med. 2015;2015:903541.
   PubMed Web of Science ®Google Scholar
• Paraskevopoulos G, Sifnaios E, Christodoulopoulos K, et al. Successful treatment of mastocytic anaphylactic episodes with reduction of skin mast cells after anti-IgE therapy. Eur Ann Allergy Clin Immunol. 2013;45(2):52–55.
   PubMedGoogle Scholar
• Kibsgaard L, Skjold T, Deleuran M, et al. Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis. Acta Derm Venereol. 2014;94(3):363–364.
   PubMed Web of Science ®Google Scholar
• Douglass JA, Carroll K, Voskamp A, et al. Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient. Allergy. 2010;65(7):926–927.
   PubMed Web of Science ®Google Scholar
• Carter MC, Robyn JA, Bressler PB, et al. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol. 2007;119(6):1550–1551.
   PubMed Web of Science ®Google Scholar
• Matito A, Blazquez-Goni C, Morgado JM, et al. Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis. Ann Allergy Asthma Immunol. 2013;111(5):425–426.
   PubMed Web of Science ®Google Scholar
• Lock AD, McNamara CJ, Rustin MH. Sustained improvement in urticaria pigmentosa and pruritus in a case of indolent systemic mastocytosis treated with cladribine. Clin Exp Dermatol. 2015;40(2):142–145.
   PubMed Web of Science ®Google Scholar
• Penack O, Sotlar K, Noack F, et al. Cladribine therapy in a patient with an aleukemic subvariant of mast cell leukemia. Ann Hematol. 2005;84(10):692–693.
   PubMed Web of Science ®Google Scholar
• Mitsuya J, Hara H, Fukuda N, et al. A case of cutaneous mastocytosis in a child with prominent Langerhans cell infiltration. Pediatr Dermatol. 2011;28(4):412–415.
   PubMed Web of Science ®Google Scholar
• Sussman G, Hebert J, Gulliver W, et al. Insights and advances in chronic urticaria: a Canadian perspective. Allergy Asthma Clin Immunol. 2015;11(1):7.
   PubMed Web of Science ®Google Scholar
• Hoffmann KM, Moser A, Lohse P, et al. Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation. Blood. 2008;112(5):1655–1657.
   PubMed Web of Science ®Google Scholar
• Marton I, Posfai E, Borbenyi Z, et al. Therapeutic challenge during the long-term follow-up of a patient with indolent systemic mastocytosis with extensive cutaneous involvement. Eur Rev Med Pharmacol Sci. 2015;19(9):1607–1609.
   PubMed Web of Science ®Google Scholar
• Morren MA, Hoppe A, Renard M, et al. Imatinib mesylate in the treatment of diffuse cutaneous mastocytosis. J Pediatr. 2013;162(1):205–207.
   PubMed Web of Science ®Google Scholar
• Pardanani A. How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage). Blood. 2013;121(16):3085–3094.
   PubMed Web of Science ®Google Scholar
• Aichberger KJ, Sperr WR, Gleixner KV, et al. Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis. Eur J Clin Invest. 2008;38(11):869–873.
   PubMed Web of Science ®Google Scholar
• Krauth MT, Fodinger M, Rebuzzi L, et al. Aggressive systemic mastocytosis with sarcoma-like growth in the skeleton, leukemic progression, and partial loss of mast cell differentiation antigens. Haematologica. 2007;92(12):e126–9.
   PubMed Web of Science ®Google Scholar
• Abid A, Malone MA, Curci K. Mastocytosis. Prim Care. 2016;43(3):505–518.
   PubMed Web of Science ®Google Scholar